Internal Medicine, Hematology & Oncology · Iowa City, IA
NPI
1558429100
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
200 Hawkins Dr
Iowa City, IA, 52242
Phone (319) 356-2324
Groups this clinician bills Medicare through
Medicare paid, 2024
$41K
811 services
Medicare patients, 2024
241
Average age 73
Drug cost, 2024
$2.0M
480 prescriptions
Company payments, 2025
$9,526
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammed M Milhem was code 99213 (office e&m - established), 356 times for 166 patients. In total Mohammed M Milhem billed 811 services in 9 codes, and Medicare paid $41K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-11-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 356 | 166 | $41.46 | $15K |
| 99214 Office E&M - Established | Facility | 277 | 140 | $68.24 | $19K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 113 | 76 | $12.07 | $1,364 |
| 99205 Office E&M - New | Facility | 24 | 24 | $121.35 | $2,912 |
By year: 2022 $46K for 839 services; 2023 $48K for 767 services; 2024 $41K for 811 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohammed M Milhem prescribed most often to Medicare patients was Mektovi (Binimetinib), with 44 prescriptions and refills. In total Mohammed M Milhem wrote 480 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mektovi Binimetinib | 44 | 44 | Under 11 | $428K |
| Braftovi Encorafenib | 39 | 41 | Under 11 | $526K |
| Levothyroxine Sodium Generic | 36 | 46 | Under 11 | $138 |
| Ondansetron Hcl Generic | 36 | 36 | 21 | $273 |
| Prednisone Generic | 30 | 37 | 18 | $128 |
| Dexamethasone Generic | 24 | 24 | 13 | $272 |
| Budesonide Dr Budesonide | 20 | 20 | Under 11 | $1,257 |
| Omeprazole Generic | 17 | 19 | Under 11 | $69.51 |
| Ogsiveo Nirogacestat Hydrobromide | 17 | 17 | Under 11 | $395K |
| Prochlorperazine Maleate Generic | 16 | 16 | Under 11 | $190 |
| Hydrocortisone Generic | 15 | 21 | Under 11 | $405 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 15 | 16 | Under 11 | $17.14 |
| Stivarga Regorafenib | 14 | 14 | Under 11 | $229K |
| Levetiracetam Generic | 12 | 16 | Under 11 | $269 |
| Gleevec Imatinib Mesylate | 11 | 15 | Under 11 | $86K |
Brand drugs: 178 claims; generic drugs: 302 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammed M Milhem $9,526 ($53.18 in general payments such as food, travel and fees and $9,473 for research) from 8 companies. The largest payer was Pfizer Inc. with $6,400.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.